JPMorgan analyst Cory Kasimov raised his price target for Seattle Genetics to $85 saying he’s bullish on the potential success of ECHELON-2, which is expected to readout in Q4. The analyst, however, thinks expectations from investors are “relatively high.” Nevertheless, another successful readout and material line extension for Adcetris could help maintain the stock’s “impressive recent momentum,” Kasimov tells investors in a research note. He keeps an Overweight rating on Seattle Genetics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.